Trastuzumab (Herceptin) for Metastatic Breast Cancer Treatment
Sep 17, 2025 · Introduction: About 10% to 20% of newly diagnosed breast cancers are HER2-positive [1-2]. HER2-positive tumors have a lot of the protein called HER2 on the surface of …
Treating HER2+ Metastatic Breast Cancer - herceptin
Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.
Adding Tucatinib to First-line Maintenance Therapy Delayed …
3 days ago · The trial enrolled 654 patients with HER2-positive advanced breast cancer who had completed four to eight cycles of induction chemotherapy plus trastuzumab and pertuzumab, …
Tucatinib Plus Trastuzumab/Pertuzumab Prolongs PFS in HER2 …
2 days ago · As such, there is an unmet need for developing more effective first-line maintenance treatments in HER2-positive metastatic breast cancer.
Adding Tukysa to First-line Maintenance Therapy Delays Metastatic ...
3 days ago · Since 2012, the first-line treatment for HER2-positive metastatic breast cancer has remained largely unchanged, consisting of chemotherapy followed by maintenance therapy …
HER2 Breast Cancer: The Basics About This Specific Subtype
1 day ago · For Your Patients: What to Know About the Newest Treatments for HR+/HER2- Breast Cancer — Resistance to initial therapy sets the stage for many other options
Adding tucatinib to first-line maintenance therapy delays disease ...
2 days ago · Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2 …
Advancing Treatment After CDK4/6 Inhibitor Progression in …
3 days ago · The efficacy of contemporary cancer treatments can be attributed to novel targeted and immunotherapeutic agents capable of selectively targeting cancer cells, such as CDK4/6 …
TUKYSA Added to First-Line Maintenance Therapy Extends …
2 days ago · TUKYSA is approved in combination with trastuzumab and capecitabine to treat adults with HER2-positive advanced unresectable or metastatic breast cancer, including …
Trastuzumab: Targeted therapy for breast cancer | LBBC
Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive …